Adding Help to an HLA-A*24:02 Tumor-Reactive γδTCR Increases Tumor Control

Adding Help to an HLA-A*24:02 Tumor-Reactive γδTCR Increases Tumor Control

γδT cell receptors (γδTCRs) recognize a broad range of malignantly transformed cells in mainly a major histocompatibility complex (MHC)-independent manner, making them valuable additions to the engineered immune effector cell therapy that currently focuses primarily on αβTCRs and chimeric antigen re...

Full description

Bibliographic Details
Main Authors: Inez Johanna, Patricia Hernández-López, Sabine Heijhuurs, Wouter Scheper, Laura Bongiovanni, Alain de Bruin, Dennis X. Beringer, Rimke Oostvogels, Trudy Straetemans, Zsolt Sebestyen, Jürgen Kuball
Format: Article
Language:English
Published: Frontiers Media S.A. 2021-10-01
Series:Frontiers in Immunology
Subjects:
cancer immunotherapy
TEGs
mouse model
preclinical (in vivo) studies
TCR engineering
human leukocyte antigens (HLA)
Online Access:https://www.frontiersin.org/articles/10.3389/fimmu.2021.752699/full

Internet

https://www.frontiersin.org/articles/10.3389/fimmu.2021.752699/full

Similar Items